The Seats at the Table: Recovering the 2015 Initiative’s Patient Advisory Board

An Absence in the Appendix

Open the 2015 initiative’s published supplements and a pattern emerges. The appendices list scientific advisory boards, data safety monitoring committees, site principal investigators, and laboratory leads. They do not list a patient advisory board. For years, that omission supported a simple inference: if patient partners had been involved, the paperwork would show it.

The archive tells a different story. Across surviving meeting minutes, recruitment flyers, internal correspondence, and successive drafts of consent documents, a patient advisory board appears—not as a ceremonial gesture, but as a working body whose interventions can be traced in the initiative’s protocols. Its members were recruited, compensated modestly, convened in person and by telephone, and asked to comment on materials that most research teams in 2015 treated as purely technical. Their names surface unevenly: full names in early attendance sheets, initials in later minutes, first names only in thank-you notes. The board existed. The published record simply did not know where to put it.

A Roster Assembled by Hand

The recovery begins with recruitment materials. A one-page flyer, undated but consistent with early 2015 typography and clinic addresses, invited patients with prior fertility treatment experience to join a “patient review panel.” The language was cautious: participants would review study information, discuss visit burden, and advise on communication. The flyer promised a modest honorarium and reimbursement for childcare and travel—details that matter, because they indicate the organizers understood that advisory service is labor.

Minutes from the first convened meeting list seven patient partners and two facilitators. The composition was deliberately varied: patients who had undergone in vitro fertilization, patients who had experienced pregnancy loss, and at least one partner of a patient. Recruitment ran through three clinic sites and two advocacy organizations. The minutes record a facilitator acknowledging that the board was “not statistically representative” and proposing that members serve as informed reviewers rather than as a survey sample. That distinction—between representation and review—would shape the board’s work and, eventually, its invisibility.

Fingerprints in the Protocol

The strongest evidence of the board’s influence lies in document versions. An early consent form described a procedure in dense clinical prose. A later draft, marked “post-PAB review,” replaced the paragraph with shorter sentences, a question-and-answer format, and a plain-language explanation of why ultrasound scheduling might vary. The change is not dramatic in isolation, but it is repeated across several documents: visit windows were widened after patient partners described travel and work constraints; reimbursement language was clarified after members reported confusion about receipts; a patient-facing summary was added to the study packet.

Correspondence between a project manager and a site investigator captures the tone of these exchanges. The manager writes that the board “pushed back hard” on a scheduling requirement, and the investigator concedes that the original timeline was designed for laboratory convenience rather than participant burden. The concession is practical, not symbolic. It altered the protocol.

Why the Board Fell Out of the Record

The board’s partial erasure appears to have been cumulative rather than deliberate. Authorship conventions in 2015 rarely accommodated patient partners; acknowledgments sections were reserved for scientific contributors or technical staff. Grant reporting forms asked for advisory committees but provided no standard field for patient boards. Confidentiality practices led staff to strip names from circulated minutes. And because the board did not vote on scientific questions, its contributions were recorded as “feedback” rather than as decisions—a classification that made them easy to omit when manuscripts were assembled.

There is also a structural reason. Patient engagement in 2015 was often described in the language of values rather than methods. Initiatives could claim to be patient-centered without documenting who advised them, how they were selected, or what changed as a result. The 2015 board fell into that gap. It was real enough to revise a consent form, but not legible enough to enter the citation trail.

Lessons for US Reproductive Research Teams

The recovery matters beyond antiquarian interest. US research teams designing advisory boards in 2026 operate under stronger expectations—from funders, institutional review boards, and participants—but the same documentary risks persist. The 2015 record suggests several practical safeguards.

First, write the board into the protocol. Specify recruitment methods, terms of service, compensation, and the scope of review. Second, document influence prospectively. A simple change log that records which documents were reviewed and what changed creates an auditable trail without exposing individual members to unwanted attention. Third, decide authorship and acknowledgment policies at the outset; patient partners who shape a consent form should not be left to a footnote added at submission. Fourth, compensate reliably and budget for access needs. The 2015 flyer’s mention of childcare was not incidental—it was a condition of participation.

Finally, distinguish engagement from endorsement. The 2015 board did not ratify the initiative’s science, and its members should not be retrofitted into a claim of consensus. What they did was more modest and more useful: they read the paperwork as patients and forced revisions that the scientific staff had not anticipated.

A decade later, the board’s absence from the appendix is no longer a neutral omission. It is a reminder that patient engagement becomes accountable only when institutions decide, in advance, that it will be recorded. The seats at the table were occupied. The archive’s task is to show who sat in them—and why the published record so nearly forgot.